Xenofon Baraliakos, EULAR 2022: Upadacitinib in the Treatment of Psoriatic Arthritis with Axial Involvement
Upadacitinib is an oral JAK1 inhibitor approved for the treatment of psoriatic arthritis. It was a pleasure to talk with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) about the impact of axial involvement on patients with psoriatic arthritis and the findings from his study investigating upadacitinib in the treatment of PsA with axial involvement.
The abstract ‘EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PROBASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES.’ (Abstract number: POS0934) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What is the impact of axial involvement on patients with psoriatic arthritis (PsA)? (0:19)
- How is axial involvement identified in patients with PsA? (1:17)
- What was the rationale for, and design of, the post-hoc analysis you are presenting? (2:23)
- What were the findings of this analysis, and how do they compare with previous data? (3:13)
- What are the clinical implications of these findings? (4:31)
Disclosures: Xenofon Baraliakos discloses consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving payment or honoraria for lectures from: Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving grant/ research support from Abbvie, Novartis and MSD; serving on advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; receiving honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; participating in speaker’s bureaus for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
